SCHEDULE: Neumora Therapeutics: Major Stakeholder Discloses Holdings

A significant Schedule 13G filing reveals Invus entities and Raymond Debbane collectively hold a 4.7% stake in Neumora Therapeutics, Inc. as of March 31, 2026.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership of Neumora Therapeutics, Inc. common stock.
• As of March 31, 2026, Invus Public Equities, L.P. directly holds 7,740,030 shares, representing 4.3% of the outstanding stock.
• Avicenna Life Sci Master Fund LP directly holds 757,792 shares, representing 0.4% of the outstanding stock.
• Several related entities (Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master GP LLC, and Ulys, L.L.C.) are disclosed as having control over these holdings.
• Raymond Debbane, through his control of Siren and Ulys, is also deemed to beneficially own the combined shares held by these entities.
• The total beneficial ownership reported by Raymond Debbane is 8,497,822 shares, representing 4.7% of the outstanding common stock.
• The outstanding shares of Neumora Therapeutics, Inc. as of March 23, 2026, were 182,040,945, based on the company's Form 10-K filed on March 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a routine disclosure of beneficial ownership and does not provide new operational or financial information about Neumora Therapeutics, Inc. itself.

Positives

• The filing indicates a substantial investment in Neumora Therapeutics, Inc. by established investment entities and individuals, suggesting confidence in the company's prospects.
• The disclosure is made in accordance with SEC regulations, ensuring transparency for investors.
• The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Negatives

• The filing does not contain any negative financial information or operational challenges; it is purely a disclosure of beneficial ownership.

Risks

• While this filing itself does not present risks, the concentration of ownership by a significant stakeholder could influence future corporate actions or strategic decisions, which may or may not align with all shareholder interests.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from Neumora Therapeutics, Inc. itself. The reporting persons certify that their holdings are not intended to influence control.

Management Comments

• Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner, certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant stakeholders to disclose their holdings in publicly traded companies. This filing indicates a notable investment in the biotechnology sector by the Invus group and Raymond Debbane.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes, potentially influencing market perception.
• Management of Neumora Therapeutics, Inc.: Awareness of substantial holdings by Invus entities and Raymond Debbane.

Next Steps

• No specific next steps are outlined in this filing beyond the standard reporting requirements.

Key Dates

Keywords

Neumora Therapeutics, Schedule 13G, Beneficial Ownership, SEC Filing, Invus, Raymond Debbane, Investment, Stock Holdings, Common Stock